Welcome to our dedicated page for Coherus BioSciences news (Ticker: $CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus BioSciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coherus BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coherus BioSciences's position in the market.
Coherus BioSciences reported net revenue of $77.1 million in Q1 2024, with significant increases in UDENYCA sales and LOQTORZI launch. The company entered into a partnership for toripalimab development, replaced term loan with new debt, and presented positive clinical data. Despite increased expenses, Coherus showed a strong financial performance, with net income of $102.9 million and cash reserves of $259.8 million.
Coherus BioSciences, Inc. announced the full repayment of a $75 million term loan through a new combined term loan and product royalty financing agreement with Barings. This move reduces the Company's term loan debt by half, with a new maturity date of May 2029. The transaction also included a $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA®.
Coherus BioSciences, Inc. announced a clinical collaboration with the Cancer Research Institute (CRI) to explore a combination of LOQTORZI (toripalimab-tpzi) with ENB-003 for the treatment of ovarian cancer. The iPROC platform study aims to investigate the potential benefits of this innovative combination in drug-resistant cancers. The selection of LOQTORZI and ENB-003 for this study is supported by strong preclinical and clinical data, with a focus on advancing meaningful solutions for patients.
Coherus BioSciences, Inc. (NASDAQ: CHRS) will report its first quarter 2024 financial results on May 9, 2024. The management team will host a conference call and webcast to discuss the results and business update. Investors can access the webcast replay and related materials on the Coherus website.